CellCentric

CellCentric

CellCentric

Drug discovery, epigenetics. Potent, selective, orally bioavailable p300/CBP inhibitors for prostate (CRPC) and other cancers.
Type
B2b
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Team Size
1–10
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when CellCentric makes some noise.